Is Grail IPO on the cards & can you buy its stock?

3 min read | December 16, 2021 07:33 AM EST | By Raza Naqvi

Highlights 

  • Potential investors are searching for Grail IPO, and the biotechnology company’s name surface on trending charts in the US.
  • Grail is working on early detection of cancer as it believes that it is important to improve treatment of the deadly disease.
  • The biopharmaceutical company has developed a test named Galleri that is capable of detecting 50 types of cancer.

Retail investors in North American markets are looking up for Grail stock as the company's name surfaced on the trending charts in the US. 

Grail is a California-based biotechnology and pharmaceutical company, and it develops products for the early detection of cancer. Using innovative technologies, data science, and next-generation sequencing (NGS) to address serious health issues by developing efficient products.

Grail is working on early detection of cancer as it believes that it is important to improve treatment of the deadly disease. According to the company website, 71 per cent of cancer deaths are caused by cancers that are not screened commonly.

The biopharmaceutical company has developed a test named Galleri that is capable of detecting 50 types of cancer. The product is designed in such a manner that only a blood sample can be used for the early detection of cancer.

Can you buy Grail stock?

In September 2020, Grail announced that it had filed for an initial public offering (IPO) with the US Securities and Exchange Commission.

 Is Grail publicly traded?

© 2021 Kalkine Media®

The biotechnology company had applied to list its shares on the Nasdaq and trade under the stock symbol GRAL. However, Grail withdrew its IPO plans after Illumina Inc. (NASDAQ:ILMN) acquired it.

Illumina completed the acquisition of Grail in August 2021 and the US Federal Trade Commission challenged the acquisition.

Also Read: Samsara IPO: How to buy the IoT software company's stock?

As Grail did not become a publicly-traded company, interested investors cannot invest their money in this stock. However, there's an alternate option of investing in Illumina as it trades on the Nasdaq and its last closing price was US$ 391.74 per share.

Bottom line

There’s no announcement from Illumina about Grail’s IPO plans. Although the acquisition is completed, it is uncertain if Illumina will make Grail a publicly-traded company.

Illumina recorded a revenue of US$ 1,108 million in Q3 2021, representing an increase of 40 per cent year-over-year (YoY).

Meanwhile, the GAAP net income of the healthcare company was US$ 317 million in the third quarter of this year.

Also Read: Reddit IPO: How to buy this discussion forum's stock?


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.